Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Mylan (MYL) shares
Learn how to easily invest in Mylan shares.
Viatris Inc (MYL) is a leading drug manufacturers-specialty & generic business based in the US. It opened the day at USD$N/A after a previous close of USD$N/A. During the day the price has varied from a low of USD$N/A to a high of USD$N/A. The latest price was USD$N/A (25 minute delay). Mylan is listed on the NASDAQ and employs 35,000 staff. All prices are listed in US Dollars.
How to buy shares in Mylan
Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
Open your brokerage account.Complete an application with your details.
Confirm your payment details.Fund your account.
Research the stock.Find the stock by name or ticker symbol – MYL – and research it before deciding if it's a good investment for you.
Purchase now or later.Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
Check in on your investment.Optimize your portfolio by tracking your stock.
Important: By investing in a share CFD, you are speculating on the price movement of that share and do not have ownership of the underlying asset. CFDs are complicated financial products are are more suited to experienced trader. Learn more about CFD trading
Use our graph to track the performance of MYL stocks over time.
Is Mylan under- or over-valued?
Valuing Mylan stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Mylan's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Mylan's P/E ratio
Mylan's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, Mylan shares trade at around 31x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Mylan's PEG ratio
Mylan's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Mylan's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Mylan's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.5 billion.
The EBITDA is a measure of a Mylan's overall financial performance and is widely used to measure a its profitability.
Operating margin TTM
Gross profit TTM
Return on assets TTM
Return on equity TTM
TTM: trailing 12 months
Mylan's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Mylan.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Mylan's total ESG risk score
Total ESG risk: 37.23
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Mylan's overall score of 37.23 (as at 01/01/2019) is pretty weak – landing it in it in the 78th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Mylan is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Mylan's environmental score
Environmental score: 1.95/100
Mylan's environmental score of 1.95 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Mylan is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Mylan's social score
Social score: 20.21/100
Mylan's social score of 20.21 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Mylan is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Mylan's governance score
Governance score: 14.07/100
Mylan's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Mylan is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Mylan's controversy score
Controversy score: 4/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Mylan scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Mylan has a damaged public profile.
Mylan share dividends
We're not expecting Mylan to pay a dividend over the next 12 months.
Have Mylan's shares ever split?
Mylan's shares were split on a 3:2 basis on 9 October 2003. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Mylan shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Mylan shares which in turn could have impacted Mylan's share price.
Mylan share price volatility
Over the last 12 months, Mylan's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mylan's is 1.4656. This would suggest that Mylan's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Mylan N. V. , together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health.
Frequently asked questions
Currently 0.912% of Mylan stocks are held by insiders and 90.496% by institutions.
Latest data suggests 35,000 work at Mylan.
Mylan's fiscal year ends in December.
Mylan's address is: Building 4, Hatfield, United Kingdom, AL10 9UL
Mylan's international securities identification number is: NL0011031208
Mylan's Committee on Uniform Securities Identification Procedures number is: 628530107
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
NEO staking involves locking up NEO tokens to earn rewards.
How likely would you be to recommend finder to a friend or colleague?
Very UnlikelyExtremely Likely
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.